Close
Leave blank for all. Otherwise, the first selected term will be the default instead of "Any".

U.S. Biotech Crops Alliance's Letter to European Commission Re Regulatory Procedure for Importing Biotech Products

Apr 28 2015
Dear Commissioner Andriukaitis, On March 12, 2015 the undersigned organizations, representing a broad section of the U.S. food and agricultural industry, provided comments on the review of the European Union's (EU) regulatory procedure for approving the import of new biotechnology products being conducted by DG SANTE. In our letter we stated that a number of core principles and commitments must result from this review (see attachment).

BIO Submits Comments to FDA on Pediatrics Stakeholders Meeting

Apr 23 2015
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to present our views on pediatric drug development at the March 25 pediatric stakeholder meeting and to submit written comments to the docket. BIO applauds the leadership of the FDA for convening the stakeholder meeting to help foster collaboration and coordination across all pediatrics stakeholders, including industry, academia, the patient advocacy community, and government, so that we can work together to develop safe and effective new therapies for children.

BIO Files Amicus Brief in Amgen v. Sandoz

Apr 23 2015
BIO has filed a friend of the court brief at the Federal Circuit in the Amgen v. Sandoz case.

BIO Submits Comments to FDA on Next Generation Sequencing

Apr 20 2015

Letter to House Committee on Judiciary Chairmen Grassley and Goodlatte and Ranking Members Leahy and Conyers re Innovation Act

Apr 14 2015
Dear Chairmen Grassley and Goodlatte and Ranking Members Leahy and Conyers, We write as leading agricultural companies and producer organizations to urge caution as the Congress considers changes to the U.S. patent system. There is a concern that the Innovation Act, as currently drafted, will discourage investment in modern agricultural tools important to rural America by making patent rights more difficult to enforce and more challenging for companies and universities to cross-license agricultural technologies.

BIO Submits Comments on ClinicalTrials.gov Expansion

Mar 22 2015
The Biotechnology Industry Organization (BIO) thanks the National Institutes of Health (NIH) and the Food and Drug Administration (FDA) for the opportunity to submit comments on the Notice of Proposed Rulemaking (NPRM) entitled Clinical Trials Registration and Results Submission.

BIO Testimony Regarding Hawaii SB 717: “AN ACT TO REPEAL THE REQUIREMENT THAT GASOLINE FOR MOTOR VEHICLES IN THE STATE INCLUDE 10% ETHANOL”

Mar 16 2015
Chairman Lee, Vice Chairman Lowen, and Members of the Committee, the Biotechnology Industry Organization (“BIO”) appreciates this opportunity to provide comments on SB 717, legislation repealing the requirement that gasoline for motor vehicles in the state include 10% ethanol. This proposal is of significant concern to BIO and its members in the State of Hawaii and throughout the country.  

BIO Comments on the Draft National IPR Policy

Mar 6 2015
BIO commends the Government of India for recognizing the critical role that intellectual property plays in innovation and for initiating a review of its policies regarding intellectual property.

BIO Response to the Alexander/Burr report

Feb 23 2015
The Biotechnology Industry Organization (BIO) thanks you for the opportunity to provide our initial thoughts on your report Innovation for Healthier Americans. BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

BIO Submits Comments on Minimal Manipulation

Feb 22 2015
The Biotechnology Industry Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance for Industry and FDA Staff entitled “Minimal Manipulation of Human Cells, Tissues, and Cellular and Tissue-Based Products” (HCT/P).